An Open-Label Phase 2 Trial of Pegylated Liposomal Doxorubicin and rIL-21 in Ovarian Cancer Patients With Persistent or Progressive Disease After, or Relapse Within One Year of, Completion of Standard First Line Therapy
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Denenicokin
- Indications Ovarian cancer
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- Sponsors Novo Nordisk
- 07 Jun 2017 Biomarkers information updated
- 12 May 2012 Official Title amended as reported by European Clinical Trials Database record.
- 28 Apr 2012 Planned number of patients changed from 10 to 100 as reported by European Clinical Trials Database record.